Ingen internetforbindelse — viser den gemte version af siden.

Equillium Inc

USUSD
← Til Screeneren
US:EQLSE:0A4D

Equillium Inc (LSE:0A4D) — Biotechnology: Pharmaceutical Preparations. Antal børser, hvor selskabets aktier handles: 2. På denne side — kurs og diagram, udbytte, største aktionærer og historik over antal aktier.

Om Virksomheden

Websted
equilliumbio.com
Sektor
Health Care · Biotechnology: Pharmaceutical Preparations
Hovedkontor
LA JOLLA, United States
Administrerende Direktør
Bruce Steel
Ansatte
14
Børsnoteret Siden
11.11.2022 (LSE:0A4D)
Udestående Aktier
63.41 mio. pr. 2026-08-07
Free Float
36.97 mio.
Markedsværdi
89.41 mio. USD
Insidere
16%
Institutionelle Investorer
65.76%
Branche (SIC)
Pharmaceutical Preparations
P/E
underskud
FCF
−20.1 mio. USD
Gæld
7.64 mio. USD
nettokasse
Indtjening og FCF — for de 12 måneder frem til 30.06.2026 (virksomhedens seneste rapport).
Beskrivelse

Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. The company develops EQ504, a novel AhR modulator that is in preclinical-stage for the treatment of ulcerative colitis and lung inflammation diseases. It also develops EQ302, a bi-specific inhibitor of IL-15 and IL-21 formulated for oral delivery for the treatment of celiac diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.

annonce

Børser og Tickere

BørsTickerValutaPrisType
US USA StocksEQ primærUSD1.5 +6.38%almindelige aktier
LSE London Stock Exchange0A4D IOBUSD1.4 +0.00%almindelige aktier

Kurs over 3 Måneder

stigningsdag faldsdagHold musen over / tryk på en dag — åbnings-, luknings-, højeste og laveste kurs

Største Ejere

EjerAndelAktierRapportdato
Jupiter Topco LLC10.24%6.49 mio.2026-06-30
Decheng Capital LLC7.01%4.45 mio.2026-06-30
Affinity Asset Advisors,…6.47%4.1 mio.2026-06-30
Adar1 Capital Management…5.93%3.76 mio.2026-06-30
Aberdeen Group plc5.73%3.63 mio.2026-06-30
abrdn Life Sciences Inve…5.73%3.63 mio.2026-06-30
Woodline Partners LP5.52%3.5 mio.2026-06-30
RA Capital Management, L…4.88%3.1 mio.2026-06-30
Stempoint Capital LP3.18%2.02 mio.2026-06-30
Vanguard Capital Managem…2.87%1.82 mio.2026-06-30
Eversept Partners, LP2.4%1.52 mio.2026-06-30
VANGUARD INDEX FUNDS-Van…2.21%1.4 mio.2026-06-30
CONNELLY STEPHEN (Presid…≈1.2%762 0252026-06-05
VANGUARD INDEX FUNDS-Van…0.54%344 4892026-06-30
Fidelity Concord Street…0.26%162 8512026-07-31
iShares Trust-iShares Mi…0.24%153 0762026-08-31
American Century ETF Tru…0.12%75 4112026-08-31
ZEDELMAYER CHRISTINE (Ch…≈0.1%62 5862026-06-05
Fidelity Concord Street…0.09%54 6772026-07-31
Fidelity Concord Street…0.07%47 4652026-07-31
Invesco Exch-Trd Fd. TRT…0.06%38 5162026-08-31
Fidelity Concord Street…0.06%36 6832026-07-31
TOM PENNY (Officer)—02026-05-28
KEYES JASON A (Chief Fin…——2025-01-23